Updated July 2026. By Remy Beaumont.
Key takeaways
Neko Health raised a $700m Series C led by Lightspeed at a valuation of nearly $7bn, before it has opened a single US clinic. The Neko Health $700m round is a bet on a queue, not a concept.
The company has 100,000 members across the UK and Sweden, is profitable at clinic level, and holds a waitlist of more than 350,000 people.
Demand built ahead of supply is the launch strategy. Scarcity did Neko's PR for years, and the US entry starts with one Manhattan clinic to keep it that way.
For founders, the lesson is that a waitlist is leverage with press, investors and customers all at once.
What happened?
Neko Health, the preventive health scanning company co-founded by Spotify's Daniel Ek and Hjalmar Nilsonne, raised a $700m Series C led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, valuing the business at close to $7bn, roughly 4x its January 2025 Series B, TechCrunch reported on 15 July. The company says it has passed 100,000 members in the UK and Sweden, is profitable at clinic level according to Sifted, and will use the funding to open its first US clinic in Manhattan later this year, backed by a waitlist of more than 350,000 people, per the company's own announcement.
Why does it matter for founders?
Neko raised one of Europe's largest ever consumer health rounds on the strength of demand it manufactured before opening capacity. The 350,000 person waitlist is not a byproduct of growth, it is the product of a deliberate scarcity strategy: few clinics, visible queues, and word of mouth from a premium experience. Investors did not fund a promise, they funded a measurable backlog of buyers.
That inverts how most founders plan a launch. The default is to build supply, announce loudly, then hope demand shows up. Neko shows the compounding value of doing it the other way round: every month of queue growth made the next raise, the next market entry and the next press cycle easier.
What does this mean for your launch?
Build the queue before the launch. Open a waitlist with a concrete promise this month, even if your product is quarters away.
Make scarcity visible. Publish your waitlist number once it is credible; it is a traction metric press can quote.
Enter new markets one city at a time. A single Manhattan clinic creates more story than ten quiet openings; concentrate your launch, do not dilute it.
Prove unit economics early. Profitable at clinic level is the line every journalist repeated; find your equivalent proof point and lead with it.
What to do this week
Set up a waitlist page with a specific promise and a reason to refer others.
Define the one unit economics metric you can defend publicly and start tracking it.
Choose the single city or segment where your launch story will concentrate.
Compare Neko's approach with other demand-first launches in our launch teardowns and this week's funding roundup, or map your own version with our launch service.
FAQ
How much did Neko Health raise? Neko Health raised $700m in Series C funding led by Lightspeed Venture Partners and co-led by O.G. Venture Partners, at a valuation of nearly $7bn.
Is Neko Health profitable? Neko Health says it is profitable at clinic level, with 100,000 members across the UK and Sweden.
When does Neko Health launch in the US? Neko Health plans to open its first US clinic in Manhattan later in 2026, supported by a waitlist of more than 350,000 people.
Who founded Neko Health? Neko Health was co-founded by Spotify founder Daniel Ek and Hjalmar Nilsonne in Stockholm.
We break down a launch like this every week. Join Ignita's free Substack at ignitaai.substack.com.
